Polaris AI Pharma announced on June 12, 2026, that it has been selected as the sole implementing institution for the “Core Pharmaceutical Stockpiling Support Project,” one of the initiatives under the “2026 Biohealth Industry Supply Chain Security Support Project.” The project is overseen by the Ministry of Health and Welfare and executed by the Korea Health Industry Development Institute.


Polaris AI Pharma Selected as Implementing Institution for "Core Pharmaceutical Stockpiling Support Project" View original image

The purpose of the project is to establish a timely supply system for pharmaceuticals whose production, import, or supply is unstable compared to demand, as well as for national essential medicines. Polaris AI Pharma will implement a strategic response system that involves the phased and parallel stockpiling of both active pharmaceutical ingredients (APIs) and finished pharmaceuticals, taking into account the characteristics of medicines that may experience a sudden surge in demand within a short period.


With its selection for this project, Polaris AI Pharma will be eligible to receive preferential drug pricing benefits from the National Health Insurance Service due to the use of national essential medicines and domestically produced ingredients. This is expected to lead to enhanced product competitiveness, increased sales, and improved profitability in the future.


The government will provide not only preferential drug pricing to companies that help minimize supply disruptions, but also support for warehouse rental fees, quality testing costs, and dedicated personnel expenses. Over the next five years, Polaris AI Pharma will collaborate with the government to maintain mandatory stockpiles of designated pharmaceuticals, serving as a key pillar of the national health security network.


In addition, Polaris AI Pharma is working to establish an “integrated operation model” that extends beyond simply securing inventory to include demand analysis, production, stockpiling, and supply response. The company plans to maintain the stability of pharmaceuticals during long-term storage by strengthening specialized storage environments and inventory management systems that meet quality control standards. A company representative stated, “Being selected as the sole implementing institution for this project proves that our company’s supply response capability is at a national level. Based on government support such as preferential drug pricing, we will manage the stockpiling scale of core pharmaceuticals stably, aiming to achieve sales growth and enhance our long-term corporate value.”



Meanwhile, Polaris AI Pharma was recently also selected as the lead institution for the “Raw Material Procurement Diversification Support Project” organized by the Ministry of Health and Welfare. The company is currently maximizing manufacturing cost savings and productivity by applying “AskDoc for Pharma,” an AI service specialized for pharmaceuticals that was co-developed with its affiliate Polaris Office, to its production sites. Based on this AI-driven manufacturing competitiveness, the company plans to target the global procurement market, including regions such as Russia and the Middle East.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing